Methods of increasing insulin sensitivity or decreasing...

Details Methods of increasing insulin sensitivity or decreasing... Methods of increasing insulin sensitivity or decreasing...

2007-01-29

2010-10-19

Landsman, Robert (Department: 1647)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S139100

Reexamination Certificate

active

07815905

ABSTRACT:
In some aspects, the invention relates to methods for increasing insulin-sensitivity and/or decreasing insulin secretion in an individual by reducing or inhibiting corticotropin releasing factor 2 (CRFR2) signaling. CRFR2 antagonists may block agonism by one or more CRFR2 agonist, for example Ucn 2 or Ucn 3. Methods according to the invention may be use to treat a variety of metabolic diseases such as type 2 diabetes, metabolic syndrome, nonalcoholic fatty liver disease, polycystic ovarian syndrome and obesity.

REFERENCES:
patent: 5109111 (1992-04-01), Rivier et al.
patent: 5245009 (1993-09-01), Kornreich et al.
patent: 5510458 (1996-04-01), Kornreich et al.
patent: 5777073 (1998-07-01), Rivier
patent: 5874227 (1999-02-01), Rivier
patent: 6323312 (2001-11-01), Rivier
patent: 6670140 (2003-12-01), Isfort et al.
patent: 6680367 (2004-01-01), Desjardins et al.
patent: 6812210 (2004-11-01), Vale et al.
patent: 6953838 (2005-10-01), Vale et al.
patent: 2002/0082409 (2002-06-01), Hsu et al.
patent: 2002/0183375 (2002-12-01), Dubowchik et al.
patent: 2004/0034882 (2004-02-01), Vale et al.
patent: 2006/0069516 (2006-03-01), Royappa
patent: 2007/0042954 (2007-02-01), Chen et al.
patent: 1097709 (2001-05-01), None
patent: WO 02/24732 (2002-03-01), None
patent: WO 02/074326 (2002-09-01), None
patent: WO 03/062277 (2003-07-01), None
patent: WO 2006/086402 (2006-08-01), None
Bale et al., “Corticotropin-Releasing Factor Receptor-2-Deficient Mice Display Abnormal Homeostatic Responses to Challenges of Increased Dietary Fat and Cold,”Endocrinology,144:2580-2587, 2003.
Brar et al., “Urocortin-II and Urocortin-III Are Cardioprotective against Ischemia Reperfusion Injury: An Essential Endogenous Cardioprotective Role for Corticotropin Releasing Factor Receptor Type 2 in the Murine Heart,”Endocrinology,145(1):24-35, 2004.
Chalmers et al., “Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression , ”J. Neuroscience,15:6340-6350, 1995.
Chen et al., “Mouse corticotropin-releasing factor receptor type 2alpha gene: isolation, distribution, pharmacological characterization and regulation by stress and glucocorticoids, ”Mol. Endocrinol.,19:441-458, 2005.
Chen et al., “Urocortin II gene is highly expressed in mouse skin and skeletal muscle tissues: localization, basal expression in corticotropin-releasing factor receptor (CRFR) 1- and CRFR2- null mice, and regulation by glucocorticoids , ”Endocrinology,145:2445-2457, 2004.
Cullen et al., “Urocortin corticotropin releasing factor-2 receptors and energy balance,”Endocrinology,142:992-999, 2001.
Florence and Yeager, “Treatment of Type 2 Diabetes Mellitus,”American Family Physician, AAFP,1999.
Gilon & Henquin, “Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function,”Endocr. Rev.,22:565-604, 2001.
Hsu and Hsueh, “Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor,”Nat. Med.,7:605-611, 2001.
Kishimoto et al., “A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle,”Proc. Natl. Acad. Sci. USA,92:1108-1112, 1995.
Kostich et al., “Molecular Identification and Analysis of a Novel Human Corticotropin-Releasing Factor (CRF) Receptor: The CRF2γ, Receptor,”Mol. Endo.,12(8):1077-1085, 1998.
Lewis et al., “Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor,”PNAS,98(13):7570-7575, 2001.
NCBI Accession No. AF011406, “Homo sapiens corticotropin releasing hormone receptor type 2 beta isoform (CRH2R) mRNA, complete cds,” 1997.
PCT International Search Report and Written Opinion, issued in International Application No. PCT/US2007/061230, dated Oct. 11, 2007.
Perrin et al., “Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart , ”Proc. Natl. Acad. Sci. USA,92:2969-2973, 1995.
Reyes et al., “Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors , ”Proc. Natl. Acad. Sci. USA,98:2843-2848, 2001.
Rijkers et al., “Structure-activity studies on the corticotropin releasing factor antagonist astressin, leading to a minimal sequence necessary for antagonistic activity,”ChemBioChem,5(3)340-348, 2004.
Rivier et al., “Potent and Long-Acting Corticotropin Releasing Factor (CRF) Receptor 2 Selective Peptide Competitive Antagonists,”J. Med. Chem.,45:4737-4747, 2002.
Rivier et al., “Role of corticotropin-releasing factor receptors type 1 and 2 in modulating the rat adrenocorticotropin response to stressors , ”Endocrinology,144:2396-403, 2003.
Shulman, “Cellular mechanisms of insulin resistance,”J. Clin. Invest.,106:171-176, 2000.
Shulman, “Unraveling the cellular mechanism of insulin resistance in humans: new insights from magnetic resonance spectroscopy,”Physiology,19:183-190, 2004.
Smith et al., “Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development ,”Neuron.,20:1093-1102, 1998.
Virkamaki et al., “Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance,”J. Clin. Invest.,103:931-943, 1999.
Zierath et al., “Insulin action and insulin resistance in human skeletal muscle,”Diabetologia,43:821-835, 2000.

Affiliated with

Also associated with

Rating

Methods of increasing insulin sensitivity or decreasing... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of increasing insulin sensitivity or decreasing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of increasing insulin sensitivity or decreasing... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4169166